Dark Genome Biotech HERVolution Therapeutics Announces $11.7M Series A to Advance Treatments for Cancer & Diseases of Aging
Hand-out
Press Releases
HERVOLUTION Therapeutics  
December 19, 2024

Dark Genome Biotech HERVolution Therapeutics Announces $11.7M Series A to Advance Treatments for Cancer & Diseases of Aging

The company engineers novel immunotherapies that empower the immune system to target HERV antigens from the dark genome to treat cancer, metabolic disease, and other aging-related diseases

avatar profile Olean Times Herald

Olean Times Herald


Local & Social